Travere Therapeutics price target lowered to $27 from $31 at BofA
BofA analyst Jason Zemansky lowered the firm’s price target on Travere Therapeutics (TVTX) to $27 from $31 and keeps a Buy rating on the shares ...
Travere Therapeutics (TVTX) Receives a Buy from Guggenheim
In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on Travere Therapeutics (TVTX – Research Report), with a ...
Investor's Business Daily on MSN23h
Novartis Has A Slight Edge On Travere — Why Analysts Aren't Worried
Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.
Fierce Pharma1d
Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $31.00
Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target increased by Bank of America from $29.00 to $31.00 in a report issued on Tuesday,Benzinga reports. Bank of America currently has a ...
Seeking Alpha27d
Travere Therapeutics: Tricky Outlook Gives Me Pause For Thought - Downgrade
Travere Therapeutics, Inc.'s Filspari received full FDA approval last September, due to its significantly reducing kidney function decline in IgA nephropathy, which boosted the company's share ...
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
Travere's late-breaking oral presentation at NKF details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS ...
pharmaphorum1d
Novartis gets FDA nod for second of three IgAN drugs
Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...
Yahoo Finance7d
Travere Therapeutics, Inc. (TVTX)
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in ...